2022
Immunity waning after COVID vaccine booster vs. infection—better than expected
Khoury J, Najjar-Debbiny R, Elemy A, Jabbour A, Haj J, Abu-Sini M, Yasin R, Amin M, Hellou E, Nasrallah N, Saffouri A, Hakim F. Immunity waning after COVID vaccine booster vs. infection—better than expected. Infectious Diseases 2022, 54: 828-831. PMID: 35796285, DOI: 10.1080/23744235.2022.2097304.Peer-Reviewed Original ResearchConceptsBooster doseSecond doseThird doseSecond boosterBNT162b2 mRNA COVID-19 vaccineMRNA COVID-19 vaccineCOVID-19 PCRIgG antibody titresBAU/mLCOVID-19 vaccineEMMS Nazareth HospitalVaccine boosterSuggestive symptomsMean titresNasopharyngeal swabsProspective studyAsymptomatic infectionDoses groupsAntibody titresBooster groupGeneral populationHigh titresDoseTitresDosesAntibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases
Harboe Z, Hamm S, Pérez-Alós L, Sivapalan P, Priemé H, Wilcke T, Kjeldgaard P, Shaker S, Jordan A, Møller D, Heftdal L, Madsen J, Bayarri-Olmos R, Hansen C, Pries-Heje M, Hasselbalch R, Fogh K, Armenteros J, Hilsted L, Sørensen E, Lindegaard B, Browatzki A, Biering-Sørensen T, Frikke-Schmidt R, Ostrowski S, Iversen K, Bundgaard H, Nielsen S, Garred P, Jensen J. Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases. BMJ Open Respiratory Research 2022, 9: e001268. PMID: 35793836, PMCID: PMC9260234, DOI: 10.1136/bmjresp-2022-001268.Peer-Reviewed Original ResearchConceptsChronic pulmonary diseaseCOVID-19 vaccinationPulmonary diseaseLow respondersRisk factorsHumoral responseBNT162b2 mRNA COVID-19 vaccineBNT162b2 COVID-19 vaccinationMRNA COVID-19 vaccineCharlson Comorbidity IndexProspective cohort studyUse of prednisolonePoor immunological responseFunctional humoral responseCOVID-19 vaccineAU/mLComorbidity indexCohort studyFirst vaccinationSecondary outcomesPrimary outcomeRBD IgGAntibody responseImmunological outcomesAntibody indexImmunogenicity and Antibody Titers After BNT162b2 mRNA COVID-19 Vaccine, Breakthrough Infection and Booster
Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M, Shkeiri R, Elemy A, Hakim F. Immunogenicity and Antibody Titers After BNT162b2 mRNA COVID-19 Vaccine, Breakthrough Infection and Booster. 2022, a3130-a3130. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3130.Peer-Reviewed Original ResearchBNT162b2 mRNA COVID-19 vaccineMRNA COVID-19 vaccineCOVID-19 vaccineBreakthrough infectionsAntibody titers
2021
COVID-19 vaccine – Long term immune decline and breakthrough infections
Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M, Shkeiri R, Elemy A, Hakim F. COVID-19 vaccine – Long term immune decline and breakthrough infections. Vaccine 2021, 39: 6984-6989. PMID: 34763949, PMCID: PMC8556595, DOI: 10.1016/j.vaccine.2021.10.038.Peer-Reviewed Original ResearchConceptsAntibody titersCOVID-19 vaccineBreakthrough infectionsSecond doseAntibody levelsPolymerase chain reactionBNT162b2 mRNA COVID-19 vaccineSARS-CoV-2 polymerase chain reactionMRNA COVID-19 vaccineStudy periodBreakthrough infection rateMedian antibody levelsMean antibody levelsLongitudinal prospective studyAntibody declineTiter elevationImmune declineProspective studyClinical indicationsMild casesHealthcare personnelInfection rateInfectionVaccinePeak levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply